HCP Live
Contagion LiveCGT LiveNeurology LiveHCP LiveOncology LiveContemporary PediatricsContemporary OBGYNEndocrinology NetworkPractical CardiologyRheumatology Netowrk

Endocrine Month in Review: April 2022

Most Popular Stories of April 2022

1. Racial/Ethnic Disparities in Eye Care for Patients with Diabetes

  • A University of Houston College of Pharmacy-led analysis of US Medical Expenditure Panel Survey data from 2009-2018 sought to assess racial/ethnic disparities in eye care for patients with diabetes.
  • In adjusted models, Hispanic and African American patients were 1.63 and 1.61 times more likely to have diabetic eye complications compared to their White counterparts and African American patients were 29% less likely to complete all of the ADA-recommended processes of diabetes care.

2. Role of CGM in Diabetes Management

  • In a recent edition of EndoView, Dr. Diana Isaacs reviews the role of CGM in diabetes management and shares considerations for the utilization and impact of CGMs in the diabetes treatment landscape.
  • Launched on April 7, the multipart series touches on emerging systems, the evolution of CGM, and patient factors when choosing a CGM system.

3. PFAS Exposure and Diabetes During Midlife in Women

  • An analysis of SWAN-MPS led by investigators at Michigan Medicine assessed associations of PFAS exposure with risk of T2D in midlife among women.
  • The 1200-woman analysis suggested women in the highest tertile of PFAS exposure were at a more than 2-fold increase in risk of developing incident diabetes compared to their counterparts in the lowest tertile of exposure.

4. Switching from MDI to AHCL Improves Glycemic Control

  • A prospective, open-label, single-arm study assessed the effects of switching from multiple daily injections to an advanced hybrid closed loop system in patients with type 1 diabetes.
  • Results indicated TIR increased from 42.1±18.7% at baseline to 78.8±6.1% in the study phase (P <.001), with mean HbA1c decreasing from 8.6±1.7% at baseline to 6.5±0.7% at the end of the study (P=.001), with no episodes of severe hypoglycemia or diabetic ketoacidosis reported during the study.

5. NSAID Use Inhibits Bisphosphonate Benefit

  • A prospective, open-label, single-arm study assessed the effects of switching from multiple daily injections to an advanced hybrid closed loop system in patients with type 1 diabetes.
  • Results indicated TIR increased from 42.1±18.7% at baseline to 78.8±6.1% in the study phase (P <.001), with mean HbA1c decreasing from 8.6±1.7% at baseline to 6.5±0.7% at the end of the study (P=.001), with no episodes of severe hypoglycemia or diabetic ketoacidosis reported during the study.

6. Prediabetes Column from Dr. Gregory Weiss

  • A recent report from the CDC and a study published in the Journal of General Internal Medicine underline the concern growing around the rising rate of prediabetes in the US.
  • In this column, Dr. Gregory Weiss discusses the importance and practicality of current screening efforts for diabetes.

7. Study Estimates Life-Years Added from Meeting T2D Treatment Goals

  • Using a diabetes-specific microsimulation model and data from NHANES, a team from University of Florida College of Pharmacy sought to assess life years added from achieving treatment goals in T2D.
  • Results of the study suggested those in the lowest population quartile for BMI, HbA1c, systolic blood pressure, and LDL-C experience life expectancy gains of 3.9, 3.8, 1.9, and 0.9 years, respectively, when compared to their counterparts in the highest quartile for each category.